We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"We're raising our price target on Eli Lilly as the obesity-drug boom rolls on" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Investing.com India and Fierce Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 9h ago.
Quick answers
Why is "We're raising our price target on Eli Lilly as the obesity-drug boom rolls on" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Eli Lilly stock reaches all-time high at 1330.0 USD By Investing.com Investing.com India · 12h ago
- Lilly breaks down Medicare Bridge boon as GLP-1 sales drive another guidance lift Fierce Pharma · 12h ago
Topics
Related trends
Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Evangeline Lilly Explains Why She Left Hollywood, Admits She 'Always Hated Being Famous'
7 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
Epic teams up with Amazon Pharmacy, Eli Lilly and Mark Cuban to launch prescription drug pricing tool
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Probing the many benefits of GLP-1 receptor agonists
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.